Notable FDA news includes approval of Moderna’s RSV vaccine expansion to at-risk younger adults and Medtronic’s clearance of a miniature defibrillation lead for pediatric use. Additionally, KalVista reported a decision delay on its hereditary angioedema drug citing FDA workload. Agency leadership signals consolidation and evolving regulatory priorities amid leadership transitions, underscoring an evolving regulatory environment for biotech stakeholders.